Arkolith/Insider Trading/PNT/Form 4

Lubner David Charles

DirectorPOINT Biopharma Global Inc. (PNT) · full profile →Form 4 · filed Dec 27, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 27, 2023Disposed to issuer(D)4K——0
Dec 26, 2023Tender(U)35K——4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 27, 2023Disposed to issuer(D)26K——0
Dec 27, 2023Disposed to issuer(D)25K——0
Dec 27, 2023Disposed to issuer(D)45K——0

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-129769) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML